US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US20030216335A1
(en)
*
|
2001-11-30 |
2003-11-20 |
Jennifer Lockridge |
Method and reagent for the modulation of female reproductive diseases and conditions
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
BRPI9908967B1
(pt)
|
1998-03-20 |
2017-05-30 |
Benitec Australia Ltd |
processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
|
CA2361201A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
US20070021979A1
(en)
*
|
1999-04-16 |
2007-01-25 |
Cosentino Daniel L |
Multiuser wellness parameter monitoring system
|
AU781598B2
(en)
*
|
1999-04-21 |
2005-06-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
EP1206558B1
(en)
|
1999-08-26 |
2008-01-09 |
Calgene LLC |
Plants with modified polyunsaturated fatty acids
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
WO2002081628A2
(en)
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
DK2361981T4
(da)
*
|
2000-03-30 |
2019-05-13 |
The Whitehead Institute For Biomedical Res |
Rna-sekvensspecifikke mediatorer af rna-interferens
|
EP2345742B1
(en)
*
|
2000-03-30 |
2014-06-11 |
The Whitehead Institute for Biomedical Research |
RNA sequence-specific mediators of RNA interference
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
WO2005003350A2
(en)
*
|
2003-06-27 |
2005-01-13 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CA2427347C
(en)
*
|
2000-10-31 |
2011-01-18 |
Commonwealth Scientific And Industrial Research Organisation |
Method and means for producing barley yellow dwarf virus resistant cereal plants
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
ES2728168T3
(es)
*
|
2000-12-01 |
2019-10-22 |
Max Planck Gesellschaft |
Moléculas pequeñas de ARN que median en la interferencia de ARN
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
WO2003035869A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
|
DE10100588A1
(de)
*
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
DE10100587C1
(de)
*
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
US20050256068A1
(en)
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
EP3231445A1
(en)
|
2001-05-18 |
2017-10-18 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
WO2003070888A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
|
WO2005014811A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
WO2003070197A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1627061B1
(en)
*
|
2001-05-18 |
2009-08-12 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2003102131A2
(en)
*
|
2002-04-22 |
2003-12-11 |
Sirna Therapeutics Inc. |
Nucleic acid mediated disruption of hiv fusogenic peptide interactions
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
WO2005078097A2
(en)
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
WO2003070887A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
WO2004097020A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase gene expression
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
EP1412371B1
(en)
|
2001-07-12 |
2016-02-24 |
University of Massachusetts |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
CA2452653A1
(en)
*
|
2001-07-17 |
2003-01-30 |
Anne Josephine Milner |
Silencing of gene expression by sirna
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
ES2546829T3
(es)
|
2001-07-23 |
2015-09-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos
|
US7456335B2
(en)
*
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
DE10163098B4
(de)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
CN1604783A
(zh)
*
|
2001-10-26 |
2005-04-06 |
里伯药品公司 |
通过rna干扰治疗纤维化疾病的药物
|
JP2005506087A
(ja)
*
|
2001-10-26 |
2005-03-03 |
リボファーマ アーゲー |
プラス鎖rnaウイルスによる感染症を処置するための2本鎖リボ核酸の使用
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
EP2213292B2
(en)
*
|
2002-02-01 |
2016-06-22 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
CA2463595A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of bcl2 gene expression using short interfering nucleic acid (sina)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
EP1710307A3
(en)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
AU2003216255A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7893248B2
(en)
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
EP1476459A4
(en)
*
|
2002-02-20 |
2005-05-25 |
Sirna Therapeutics Inc |
INHIBITION OF EXPRESSION OF THE CHROMOSOME TRANSLOCATION GENE AGENT BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
EP1741781A3
(en)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8232383B2
(en)
*
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
CA2457528C
(en)
*
|
2002-02-20 |
2011-07-12 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
|
US20090247613A1
(en)
*
|
2002-02-20 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2003207708A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
AU2003219818A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Incorporated |
RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2005517433A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるTNFおよびTNFレセプタースーパーファミリー遺伝子発現のRNA干渉媒介性阻害
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
AU2003211058A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
EP1436314A4
(en)
*
|
2002-02-20 |
2005-08-10 |
Sirna Therapeutics Inc |
INHIBITION OF EXPRESSION OF THE CYCLIN D1 GENE THROUGH RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US7662952B2
(en)
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
AU2003214247B2
(en)
|
2002-03-21 |
2010-09-09 |
Monsanto Technology Llc |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US7166771B2
(en)
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
MXPA04010282A
(es)
|
2002-04-18 |
2005-08-18 |
Acuity Pharmaceuticals Inc |
Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
US7399586B2
(en)
|
2002-05-23 |
2008-07-15 |
Ceptyr, Inc. |
Modulation of biological signal transduction by RNA interference
|
US20040033602A1
(en)
*
|
2002-06-12 |
2004-02-19 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
ATE405658T1
(de)
|
2002-07-26 |
2008-09-15 |
Basf Plant Science Gmbh |
Neue selektionsverfahren
|
ES2389024T3
(es)
*
|
2002-08-05 |
2012-10-22 |
Silence Therapeutics Aktiengesellschaft |
Moléculas de RNA interferentes de extremos romos
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040241854A1
(en)
*
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
MXPA05001355A
(es)
|
2002-08-05 |
2005-09-30 |
Atugen Ag |
Formas nuevas adicionales de moleculas de arn de interferencia.
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
AU2003246349B2
(en)
|
2002-08-07 |
2011-02-03 |
Basf Plant Science Gmbh |
Nucleic acid sequences encoding proteins associated with abiotic stress response
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
US7700758B2
(en)
|
2002-08-12 |
2010-04-20 |
New England Biolabs, Inc. |
Methods and compositions relating to gene silencing
|
EP1393742A1
(en)
|
2002-08-14 |
2004-03-03 |
atugen AG |
Use of protein kinase N beta
|
BRPI0313733A8
(pt)
|
2002-08-14 |
2016-08-16 |
Atugen Ag |
Uso da proteína n beta cinase
|
WO2004022075A1
(en)
|
2002-09-04 |
2004-03-18 |
Novartis Ag |
Treatment of neurological disorders by dsrna adminitration
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20040053289A1
(en)
*
|
2002-09-09 |
2004-03-18 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
EP1575518A4
(en)
|
2002-10-10 |
2007-08-22 |
Wyeth Corp |
COMPOSITIONS, ORGANISMS AND METHODS WITH A NEW HUMAN KINASE
|
EP2072619A1
(en)
|
2002-10-18 |
2009-06-24 |
Silence Therapeutics Aktiengesellschaft |
Factor involved in metastasis and uses thereof
|
US7208306B2
(en)
|
2002-10-24 |
2007-04-24 |
Wyeth |
Compositions employing a novel human protein phosphatase
|
NZ540779A
(en)
|
2002-11-01 |
2008-05-30 |
Univ Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
EP1560839A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
CN1708320A
(zh)
*
|
2002-11-07 |
2005-12-14 |
郎基·常 |
经修饰的树突状细胞
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7611839B2
(en)
|
2002-11-21 |
2009-11-03 |
Wyeth |
Methods for diagnosing RCC and other solid tumors
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
US7297525B2
(en)
|
2002-11-27 |
2007-11-20 |
Wyeth |
Composition employing a novel human kinase
|
ATE477337T1
(de)
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
|
AU2004213452A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
EP2216407B1
(en)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
DE602004023279D1
(de)
*
|
2003-03-21 |
2009-11-05 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
CA2521464C
(en)
|
2003-04-09 |
2013-02-05 |
Alnylam Pharmaceuticals, Inc. |
Irna conjugates
|
US20090298914A1
(en)
*
|
2003-04-15 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20070270360A1
(en)
*
|
2003-04-15 |
2007-11-22 |
Sirna Therapeutics, Inc. |
Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
|
WO2005014828A2
(en)
|
2003-08-01 |
2005-02-17 |
Basf Plant Science Gmbh |
Process for the production of fine chemicals in plants
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
AU2004232964B2
(en)
|
2003-04-17 |
2011-09-22 |
Alnylam Pharmaceuticals, Inc. |
Protected monomers
|
EP1620544B1
(en)
|
2003-04-17 |
2018-09-19 |
Alnylam Pharmaceuticals Inc. |
MODIFIED iRNA AGENTS
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
CA2522730A1
(en)
|
2003-04-18 |
2004-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
|
EP3222294A1
(en)
|
2003-04-30 |
2017-09-27 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
BRPI0410886A
(pt)
*
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
US7595306B2
(en)
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
EP1633770B1
(en)
|
2003-06-13 |
2015-04-29 |
Alnylam Europe AG |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
CA2530248A1
(en)
*
|
2003-06-25 |
2005-01-06 |
Gencia Corporation |
Modified vectors for organelle transfection
|
WO2005007859A2
(en)
*
|
2003-07-11 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
KR20110007263A
(ko)
|
2003-08-28 |
2011-01-21 |
노파르티스 아게 |
블런트-말단 및 3'-변형체를 갖는 간섭 rna 이중나선
|
US20070202505A1
(en)
*
|
2003-09-08 |
2007-08-30 |
Alex Chenchik |
Methods for gene function analysis
|
WO2005045037A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1694842B1
(en)
*
|
2003-11-04 |
2011-03-23 |
Geron Corporation |
Rna amidates and thioamidates for rnai
|
JP5654722B2
(ja)
*
|
2003-11-26 |
2015-01-14 |
ユニバーシティ オブ マサチューセッツ |
短鎖rna機能の配列特異的阻害法
|
CN1922332B
(zh)
|
2003-12-31 |
2013-06-12 |
宾夕法尼亚州研究基金会 |
预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
|
DK1713912T3
(da)
*
|
2004-01-30 |
2013-12-16 |
Santaris Pharma As |
Modificerede Korte Interfererende RNA (Modificerede siRNA)
|
EP2330111A3
(en)
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
US20070269889A1
(en)
*
|
2004-02-06 |
2007-11-22 |
Dharmacon, Inc. |
Stabilized siRNAs as transfection controls and silencing reagents
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
AU2005213464A1
(en)
|
2004-02-06 |
2005-08-25 |
Wyeth |
Diagnosis and therapeutics for cancer
|
WO2005078848A2
(en)
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
EP1737493B1
(en)
|
2004-02-25 |
2011-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth
|
EP2899278A1
(en)
|
2004-03-12 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050226865A1
(en)
|
2004-04-02 |
2005-10-13 |
Regents Of The University Of California |
Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin
|
AU2005238034A1
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of hairless protein mRNA
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP2290074B1
(en)
|
2004-05-28 |
2014-12-17 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
US20060040876A1
(en)
*
|
2004-06-10 |
2006-02-23 |
Rong-Hwa Lin |
Modulation of peroxisome proliferator-activated receptors
|
ATE501252T1
(de)
|
2004-06-22 |
2011-03-15 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
CA2572439A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
EP1765857A2
(en)
|
2004-07-02 |
2007-03-28 |
Metanomics GmbH |
Process for the production of fine chemicals
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP2484780A1
(en)
|
2004-07-23 |
2012-08-08 |
The University of North Carolina At Chapel Hill |
Methods and materials for determining pain sensibility and predicting and treating related disorders
|
CN101001951B
(zh)
|
2004-08-02 |
2011-06-15 |
巴斯福植物科学有限公司 |
分离转录终止序列的方法
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
AU2005272816B2
(en)
|
2004-08-10 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides
|
CA2577423C
(en)
|
2004-08-16 |
2012-11-06 |
Quark Biotech, Inc. |
Therapeutic uses of inhibitors of rtp801
|
US20080255065A1
(en)
*
|
2004-08-18 |
2008-10-16 |
Genesense Technologies, Inc. |
Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
EP1794304B1
(en)
|
2004-09-24 |
2013-06-19 |
BASF Plant Science GmbH |
Plant cells and plants with increased tolerance to environmental stress
|
DK1799269T3
(da)
|
2004-09-28 |
2016-10-03 |
Quark Pharmaceuticals Inc |
Oligoribonukleotider og fremgangsmåder til anvendelse deraf til behandling af alopeci, akut nyresvigt og andre sygdomme
|
EP2166098B1
(en)
|
2004-10-05 |
2013-11-06 |
SunGene GmbH |
Constitutive expression cassettes for regulation of plant expression
|
CA2583722C
(en)
|
2004-10-13 |
2012-04-24 |
University Of Georgia Research Foundation, Inc. |
Nematode resistant transgenic plants
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
EP1655364A3
(en)
|
2004-11-05 |
2006-08-02 |
BASF Plant Science GmbH |
Expression cassettes for seed-preferential expression in plants
|
EP2287303B1
(en)
|
2004-11-12 |
2014-07-02 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
EP1662000B1
(en)
|
2004-11-25 |
2011-03-30 |
SunGene GmbH |
Expression cassettes for guard cell-preferential expression in plants
|
EP1666599A3
(en)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
|
EP1669455B1
(en)
|
2004-12-08 |
2009-10-28 |
SunGene GmbH |
Expression cassettes for vascular tissue-preferential expression in plants
|
EP1669456A3
(en)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for meristem-preferential expression in plants
|
MX2007007040A
(es)
|
2004-12-17 |
2008-10-24 |
Metanomics Gmbh |
Proceso para el control de produccion de productos quimicos finos.
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
EP2992902A1
(en)
|
2004-12-27 |
2016-03-09 |
Silence Therapeutics GmbH |
Lipid complexes coated with peg and their uses
|
EP1838875A4
(en)
*
|
2004-12-30 |
2010-08-25 |
Todd M Hauser |
COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING SELF-PROTECTED OLIGONUCLEOTIDES
|
WO2006072887A1
(en)
|
2005-01-05 |
2006-07-13 |
Eyegate Pharma Sa |
Ocular iontophoresis device for delivering sirna and aptamers
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
TW200639252A
(en)
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
EP2186903A3
(en)
|
2005-02-09 |
2010-09-08 |
BASF Plant Science GmbH |
Expression cassettes for regulation of expression in monocotyledonous plants
|
US20090031440A1
(en)
|
2005-02-26 |
2009-01-29 |
Basf Plant Science Gmbh |
Expression Cassettes for Seed-Preferential Expression in Plants
|
JPWO2006093083A1
(ja)
*
|
2005-03-03 |
2008-08-07 |
和光純薬工業株式会社 |
架橋剤、架橋法、遺伝子発現調節法及び遺伝子機能調査法
|
CA2599405A1
(en)
|
2005-03-08 |
2006-09-14 |
Basf Plant Science Gmbh |
Expression enhancing intron sequences
|
JP2008533050A
(ja)
|
2005-03-11 |
2008-08-21 |
アルコン,インコーポレイテッド |
緑内障を処置するためのフリッツルド関連蛋白質―1のrnai媒介性阻害
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ, インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット2の阻害剤およびその使用
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
CA2604885A1
(en)
|
2005-04-07 |
2006-10-19 |
Guoying Yu |
Cacna1e in cancer diagnosis, detection and treatment
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
JP4967137B2
(ja)
*
|
2005-04-18 |
2012-07-04 |
国立大学法人浜松医科大学 |
癌治療用組成物
|
EP1882037A2
(en)
|
2005-05-10 |
2008-01-30 |
BASF Plant Science GmbH |
Expression cassettes for seed-preferential expression in plants
|
WO2006124699A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
FR2885808B1
(fr)
|
2005-05-19 |
2007-07-06 |
Oreal |
Vectorisation de dsrna par des particules cationiques et utilisation topique.
|
BRPI0612671A2
(pt)
|
2005-06-23 |
2010-11-30 |
Basf Plant Science Gmbh |
métodos melhorados para a produção de plantas férteis zea mays (milho) estavelmente transformadas
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
EP1764107A1
(en)
*
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
CA2620387C
(en)
|
2005-09-20 |
2018-09-18 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-sirna
|
EP1934348B1
(en)
|
2005-10-11 |
2018-05-02 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compositions for silencing the expression of vdac1 and uses thereof
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
AU2006311725B2
(en)
|
2005-11-04 |
2011-11-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of NAV1.8 gene
|
US8362323B2
(en)
|
2005-11-08 |
2013-01-29 |
Basf Plant Science Gmbh |
Use of armadillo repeat (ARM1) polynucleotides for obtaining pathogen resistance in plants
|
EP2363134B1
(en)
|
2005-11-09 |
2014-01-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor V Leiden mutant gene
|
EP2463388B1
(en)
|
2005-11-29 |
2017-11-22 |
Cambridge Enterprise Limited |
Markers for breast cancer
|
US9267937B2
(en)
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
MX2008008548A
(es)
|
2005-12-30 |
2008-09-10 |
Evonik Roehm Gmbh |
Peptidos utiles como petidos penetradores de celulas.
|
CA2636070A1
(en)
|
2006-01-06 |
2007-08-02 |
North Carolina State University |
Cyst nematode resistant transgenic plants
|
EP1979484B1
(en)
|
2006-01-12 |
2014-03-19 |
BASF Plant Science GmbH |
Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
WO2007085485A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
CN101421406B
(zh)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
用于产生改变的种子油组成的核酸构建体和方法
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
AU2007229161B2
(en)
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
US8968702B2
(en)
|
2006-03-30 |
2015-03-03 |
Duke University |
Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
|
NZ571568A
(en)
|
2006-03-31 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
|
CA2644273A1
(en)
|
2006-04-05 |
2008-03-27 |
Metanomics Gmbh |
Process for the production of a fine chemical
|
EP2012827A2
(en)
|
2006-04-13 |
2009-01-14 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancer
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
JP5630998B2
(ja)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
機能的粒子のためのポリマー
|
EP2392583A1
(en)
|
2006-05-19 |
2011-12-07 |
Alnylam Europe AG. |
RNAi modulation of Aha and therapeutic uses thereof
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
EP2026843A4
(en)
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
THERAPEUTIC USES OF RTP801L INHIBITORS
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
CN101511181B
(zh)
|
2006-07-11 |
2013-08-21 |
新泽西医科和牙科大学 |
蛋白、编码该蛋白的核酸和相关的应用方法
|
CA2658550C
(en)
|
2006-07-21 |
2018-06-19 |
Silence Therapeutics Ag |
Means for inhibiting the expression of protein kinase 3
|
US7666423B2
(en)
|
2006-07-28 |
2010-02-23 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
WO2008036638A2
(en)
|
2006-09-18 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of scap and therapeutic uses thereof
|
CA2663581C
(en)
|
2006-09-21 |
2016-03-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the hamp gene
|
AU2007299705B2
(en)
*
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US9279127B2
(en)
*
|
2006-11-01 |
2016-03-08 |
The Medical Research Fund At The Tel-Aviv Sourasky Medical Center |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US20080199475A1
(en)
|
2006-11-27 |
2008-08-21 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2202314B1
(en)
|
2007-01-15 |
2014-03-12 |
BASF Plant Science GmbH |
Use of subtilisin (RNR9) polynucleotides for achieving a pathogen resistance in plants
|
JP2010516786A
(ja)
|
2007-01-26 |
2010-05-20 |
ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッド |
ワクチンとしての使用のためのエキソソーム成分の改変
|
WO2008098165A2
(en)
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
BRPI0808008B1
(pt)
|
2007-02-16 |
2016-08-09 |
Basf Plant Science Gmbh |
molécula de ácido nucleico isolada, cassete de expressão, vetor de expressão, métodos para excisão de sequências alvo de uma planta, para produzir uma planta com rendimento aumentado, e/ou tolerância a estresse aumentada, e/ou qualidade nutritional aumentada, e/ou teor de óleo aumentado ou modificado de uma semente ou broto para a planta, e, uso da molécula de ácido nucleico
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
AU2008228814B2
(en)
|
2007-03-21 |
2014-03-06 |
Brookhaven Science Associates, Llc |
Combined hairpin-antisense compositions and methods for modulating expression
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
US7759320B2
(en)
|
2007-03-29 |
2010-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
JP2010523595A
(ja)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリ(アミノ酸)ターゲッティング部分
|
AU2008242842B2
(en)
|
2007-04-17 |
2014-06-05 |
Baxter Healthcare Sa |
Nucleic acid microparticles for pulmonary delivery
|
EP2152903A2
(en)
|
2007-04-26 |
2010-02-17 |
Ludwig Institute for Cancer Research, Ltd. |
Methods for diagnosing and treating astrocytomas
|
US20100291042A1
(en)
|
2007-05-03 |
2010-11-18 |
The Brigham And Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
PL2162538T3
(pl)
|
2007-05-22 |
2016-10-31 |
|
Oligomery do zastosowań terapeutycznych
|
BRPI0811843A2
(pt)
|
2007-05-22 |
2014-10-07 |
Basf Plant Science Gmbh |
Métodos para a produção de uma planta transgênica, e para seleção de antagonistas, molécula, iniciador, mutante dominante negativo de um polipeptídeo, construto de ácido nucleico, vetor, célula de planta transgênica, planta ou uma parte da mesma, polipeptídeo isolado, anticorpo, tecido de planta, planta, material de planta colhido ou material de propagação de uma planta, processos para a produção de um polipeptídeo, e para a identificação de um composto, composição, e, uso da molécula de ácido nucleico, do construto de ácido nucleico e do vetor
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
SI2170403T1
(sl)
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
|
CA2692503C
(en)
|
2007-07-05 |
2013-09-24 |
Novartis Ag |
Dsrna for treating viral infection
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
EP2185719B1
(en)
|
2007-08-02 |
2013-11-13 |
NovImmune SA |
Anti-rantes antibodies and methods of use thereof
|
WO2009029173A1
(en)
|
2007-08-23 |
2009-03-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptogenesis
|
US8183221B2
(en)
|
2007-09-05 |
2012-05-22 |
Medtronic, Inc. |
Suppression of SCN9A gene expression and/or function for the treatment of pain
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
JP2010538678A
(ja)
*
|
2007-09-18 |
2010-12-16 |
イントラドイグム コーポレーション |
K−rassiRNA含有組成物及びそれらの使用法
|
US20100280097A1
(en)
*
|
2007-09-18 |
2010-11-04 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
DK2195428T3
(da)
|
2007-09-19 |
2014-03-03 |
Applied Biosystems Llc |
Sirna sekvens-uafhængige modifikationsformater til reducering af target-forfejlende fænotypiske effekter ved rnai, og stabiliserede former deraf
|
ES2376175T3
(es)
|
2007-09-28 |
2012-03-09 |
Bind Biosciences, Inc. |
Direccionamiento a células de c�?ncer usando nanopart�?culas.
|
CN101815521B
(zh)
|
2007-10-03 |
2014-12-10 |
夸克制药公司 |
新siRNA结构
|
US10736848B2
(en)
|
2007-10-12 |
2020-08-11 |
Massachusetts Institute Of Technology |
Vaccine nanotechnology
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
US20090247608A1
(en)
|
2007-12-04 |
2009-10-01 |
Alnylam Pharmaceuticals, Inc. |
Targeting Lipids
|
JP5530933B2
(ja)
|
2007-12-10 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
第vii因子遺伝子発現阻害のための組成物及び方法
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
CN101952444A
(zh)
*
|
2007-12-21 |
2011-01-19 |
巴斯夫植物科学有限公司 |
产量提高的植物(ko nue)
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
CA2717496A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
EP2283133A2
(en)
|
2008-04-04 |
2011-02-16 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
WO2009144704A2
(en)
|
2008-04-15 |
2009-12-03 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS FOR INHIBITING NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
EP2293800B1
(en)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
EP2323695B1
(en)
|
2008-08-19 |
2018-12-05 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
WO2010028054A1
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
EP2165710A1
(en)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
|
US8664189B2
(en)
|
2008-09-22 |
2014-03-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in skin indications
|
JP2012513953A
(ja)
|
2008-09-23 |
2012-06-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
BRPI0920827A2
(pt)
|
2008-09-29 |
2015-08-18 |
Monsanto Technology Llc |
Evento transgênico da soja mon87705 e métodos para detecção do mesmo
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
CN102245772A
(zh)
|
2008-10-15 |
2011-11-16 |
索马根尼科斯公司 |
抑制基因表达的短发卡rna
|
ES2656516T3
(es)
|
2008-10-20 |
2018-02-27 |
Alnylam Pharmaceuticals, Inc. |
Composiciones y métodos para inhibir la expresión de transtiretina
|
WO2010054221A2
(en)
|
2008-11-06 |
2010-05-14 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
EP2687609B1
(en)
|
2008-11-10 |
2017-01-04 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method for treating solid tumor
|
KR102264822B1
(ko)
|
2008-11-10 |
2021-06-14 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
AU2009322290B2
(en)
|
2008-12-03 |
2016-06-16 |
Arcturus Therapeutics, Inc. |
Una oligomer structures for therapeutic agents
|
US8470792B2
(en)
|
2008-12-04 |
2013-06-25 |
Opko Pharmaceuticals, Llc. |
Compositions and methods for selective inhibition of VEGF
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
EP2198879A1
(en)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
WO2010077894A2
(en)
|
2008-12-16 |
2010-07-08 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2658626T3
(es)
*
|
2009-02-12 |
2018-03-12 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
|
CN101525388B
(zh)
*
|
2009-02-20 |
2012-02-01 |
中国人民解放军第四军医大学 |
特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
EP2403863B1
(en)
|
2009-03-02 |
2013-08-28 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
CN102421900B
(zh)
|
2009-03-12 |
2015-07-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107955A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
KR20110138223A
(ko)
|
2009-03-27 |
2011-12-26 |
머크 샤프 앤드 돔 코포레이션 |
짧은 간섭 핵산 (siNA)을 사용한 세포간 부착 분자 1 (ICAM-1) 유전자 발현의 RNA 간섭 매개 억제
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
EP2411019A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
US10519458B2
(en)
|
2009-04-22 |
2019-12-31 |
Basf Plant Science Company Gmbh |
Whole seed specific promoter
|
BRPI1007708A2
(pt)
|
2009-05-05 |
2020-08-18 |
Beeologics Inc |
agente do ácido nucleico isolado, construção de ácido nucleico, ácido nucleico isolado, composição ingerível pelas abelhas, método para reduzir a susceptibilidade de uma abelha a infecção por nosema e método para reduzir a susceptibilidade das abelhas melíferas à infecçção por nosema
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
EA028860B1
(ru)
|
2009-06-10 |
2018-01-31 |
Арбутус Биофарма Корпорэйшн |
Улучшенная липидная композиция
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
WO2010148013A2
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsrna targeting the pcsk9 gene
|
EP2451958A1
(en)
|
2009-07-10 |
2012-05-16 |
BASF Plant Science Company GmbH |
Expression cassettes for endosperm-specific expression in plants
|
US8871730B2
(en)
|
2009-07-13 |
2014-10-28 |
Somagenics Inc. |
Chemical modification of short small hairpin RNAs for inhibition of gene expression
|
ES2562463T3
(es)
|
2009-07-14 |
2016-03-04 |
Mayo Foundation For Medical Education And Research |
Administración no covalente, mediada por péptidos, de agentes activos a través de la barrera hematoencefálica
|
KR101733255B1
(ko)
|
2009-07-20 |
2017-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 상승작용적 치료를 위한 항ctla4 항체와 다양한 치료 요법의 조합
|
BR112012001463A2
(pt)
|
2009-07-24 |
2016-03-15 |
Univ California |
métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US20110039789A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Institut Curie |
Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
|
US8916693B2
(en)
|
2009-09-17 |
2014-12-23 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
AU2010321582B2
(en)
|
2009-11-23 |
2014-08-21 |
Aquabounty Technologies, Inc. |
Maternally induced sterility in animals
|
EP2504435B1
(en)
|
2009-11-26 |
2019-11-13 |
Quark Pharmaceuticals, Inc. |
Sirna compounds comprising terminal substitutions
|
AU2010325720A1
(en)
|
2009-12-03 |
2012-07-19 |
Basf Plant Science Company Gmbh |
Expression cassettes for embryo-specific expression in plants
|
EP2509628B1
(en)
|
2009-12-07 |
2017-10-25 |
The Johns Hopkins University |
Sr-bi as a predictor of human female infertility and responsiveness to treatment
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
KR101692063B1
(ko)
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
hsp47 발현의 조절
|
EP2510098B1
(en)
|
2009-12-09 |
2015-02-11 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
EP2509590B1
(en)
|
2009-12-10 |
2019-10-30 |
The Trustees of Columbia University in the City of New York |
Histone acetyltransferase activators and uses thereof
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
AR079494A1
(es)
|
2009-12-18 |
2012-02-01 |
Novartis Ag |
Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1
|
SG10201407996PA
(en)
|
2009-12-23 |
2015-01-29 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
MX344543B
(es)
|
2010-01-26 |
2016-12-19 |
Nat Jewish Health |
Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
CN105131067B
(zh)
|
2010-03-24 |
2019-02-19 |
雷克西制药公司 |
皮肤与纤维化症候中的rna干扰
|
US8945927B2
(en)
|
2010-03-29 |
2015-02-03 |
Universite De Strasbourg |
Polymers for delivering molecules of interest
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
EP3061824B1
(en)
|
2010-04-23 |
2018-08-29 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-enac-related diseases
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
HIF-2α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
EP3190187A1
(en)
|
2010-05-21 |
2017-07-12 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
US20110293700A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
WO2011151321A1
(en)
|
2010-05-31 |
2011-12-08 |
Institut Curie |
Asf1b as a prognosis marker and therapeutic target in human cancer
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
US20130236968A1
(en)
|
2010-06-21 |
2013-09-12 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
EP2601293B1
(en)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
AR083445A1
(es)
|
2010-10-14 |
2013-02-27 |
Univ Mie |
siARN CONTRA LA FIBROSIS
|
BR112013009196A2
(pt)
|
2010-10-15 |
2020-08-25 |
The Trustees Of Columbia University In The City Of New York |
usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
PL2635299T3
(pl)
|
2010-11-02 |
2020-03-31 |
The Trustees Of Columbia University In The City Of New York |
Sposoby leczenia zaburzeń utraty włosów
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
EP2455456A1
(en)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Use of kinesin inhibitors in HIV infection treatment and a method for screening them
|
AU2011338682B2
(en)
|
2010-12-06 |
2017-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising threose modifications
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012102793A2
(en)
|
2010-12-10 |
2012-08-02 |
Zirus, Inc. |
Mammalian genes involved in toxicity and infection
|
JP6616057B2
(ja)
|
2010-12-22 |
2019-12-04 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ヒストンアセチル基転移酵素モジュレーターおよびその使用
|
US20140056811A1
(en)
|
2010-12-27 |
2014-02-27 |
Compugen Ltd. |
New cell-penetrating peptides and uses thereof
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
CN103492572A
(zh)
|
2011-03-03 |
2014-01-01 |
夸克医药公司 |
用于治疗肺疾病和损伤的组合物和方法
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
CA2828544A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
WO2012119764A1
(en)
|
2011-03-08 |
2012-09-13 |
Società Bulloneria Europea S.B.E. Spa |
A high load flanged fastener to be installed by tensioning tools
|
WO2012125872A2
(en)
|
2011-03-15 |
2012-09-20 |
University Of Utah Research Foundation |
Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
|
KR101291668B1
(ko)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
미코박테리아―대장균용 셔틀 벡터 및 이의 용도
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
CA3191066A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
WO2012177906A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
EP2723861A4
(en)
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
KR20140057374A
(ko)
|
2011-09-02 |
2014-05-12 |
노파르티스 아게 |
Hsf1-관련 질환을 치료하기 위한 유기 조성물
|
BR112014005104A2
(pt)
|
2011-09-02 |
2017-07-04 |
Salk Inst For Biological Studi |
inibidores camkii, ip3r, calcineurin, p38 e mk2/3 para tratar atar distúrbios metabólicos de obesidade
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
EP3456317A1
(en)
|
2011-09-27 |
2019-03-20 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
EP3960726A1
(en)
|
2011-10-18 |
2022-03-02 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
CN103917647B
(zh)
|
2011-11-03 |
2020-07-10 |
夸克制药公司 |
用于神经保护的方法和组合物
|
WO2013070821A1
(en)
|
2011-11-08 |
2013-05-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
KR101371696B1
(ko)
|
2012-02-02 |
2014-03-07 |
세종대학교산학협력단 |
벼도열병 발병인자의 스크리닝 방법
|
WO2013119880A1
(en)
|
2012-02-07 |
2013-08-15 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
HUE040127T2
(hu)
|
2012-03-29 |
2019-02-28 |
Univ Columbia |
Eljárások hajhullási rendellenességek kezelésére
|
WO2013166004A2
(en)
|
2012-05-02 |
2013-11-07 |
Novartis Ag |
Organic compositions to treat kras-related diseases
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
WO2013170960A1
(en)
|
2012-05-16 |
2013-11-21 |
Silence Therapeutics Ag |
Use of vegfr1 as a biomarker for pkn3 inhibitor administration
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
DK2867368T3
(da)
|
2012-07-06 |
2022-01-31 |
Roussy Inst Gustave |
Samtidig detektering af kannibalisme og senescens som prognostisk markør for cancer
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
WO2014018554A1
(en)
|
2012-07-23 |
2014-01-30 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
WO2014058915A2
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
WO2014068072A1
(en)
|
2012-10-31 |
2014-05-08 |
Institut Gustave-Roussy |
Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
|
EP2961843A2
(en)
|
2013-02-28 |
2016-01-06 |
Arrowhead Research Corporation |
Organic compositions to treat epas1-related diseases
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
ES2887254T3
(es)
|
2013-03-08 |
2021-12-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
EP3699592A1
(en)
|
2013-03-13 |
2020-08-26 |
Geneweave Biosciences Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
JP6566933B2
(ja)
|
2013-03-15 |
2019-08-28 |
サッター ベイ ホスピタルズ |
ガンを治療するための療法のための標的として使用するためのfalz
|
JP2016515508A
(ja)
|
2013-03-15 |
2016-05-30 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
融合タンパク質及びその方法
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
CN105407974A
(zh)
|
2013-07-03 |
2016-03-16 |
希望之城 |
抗癌组合
|
ES2675362T3
(es)
|
2013-07-10 |
2018-07-10 |
Basf Se |
ARNi para el control de hongos y oomicetos fitopatógenos mediante la inhibición de la expresión de genes CYP51
|
UA122662C2
(uk)
|
2013-07-19 |
2020-12-28 |
Монсанто Текнолоджі Ллс |
Композиція та спосіб боротьби з leptinotarsa
|
US20160208247A1
(en)
|
2013-07-31 |
2016-07-21 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
EP3027222A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
US10245388B2
(en)
|
2013-08-08 |
2019-04-02 |
Global Bio Therapeutics, Inc. |
Injection device for minimally invasive procedures and uses thereof
|
JP6297692B2
(ja)
|
2013-08-08 |
2018-03-20 |
グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. |
低侵襲処置用クランプデバイスおよびその使用
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
B型肝炎ウイルスを治療するための有機化合物
|
JP6694811B2
(ja)
|
2013-10-04 |
2020-05-20 |
ノバルティス アーゲー |
RNA干渉に使用するためのRNAi剤用の3’末端キャップ
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
JP6672156B2
(ja)
|
2013-11-11 |
2020-03-25 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸(siNA)の全身性送達
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
ES2774968T3
(es)
|
2013-12-19 |
2020-07-23 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
JP6372930B2
(ja)
|
2013-12-27 |
2018-08-15 |
国立大学法人高知大学 |
悪性腫瘍の治療薬
|
US10100313B2
(en)
|
2014-02-10 |
2018-10-16 |
Institut Curie |
Use of Mcoln-1 modulators to regulate cell migration
|
CN106103475B
(zh)
|
2014-03-11 |
2021-01-12 |
塞勒克提斯公司 |
产生同种异体移植相容的t细胞的方法
|
EP3122365B1
(en)
|
2014-03-25 |
2023-05-03 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
WO2015148580A2
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Una oligomers having reduced off-target effects in gene silencing
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
SG10201808565QA
(en)
|
2014-03-31 |
2018-11-29 |
Debiopharm Int Sa |
Fgfr fusions
|
WO2015153339A2
(en)
|
2014-04-01 |
2015-10-08 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
KR101633881B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
|
KR101633876B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
|
WO2016011123A1
(en)
|
2014-07-16 |
2016-01-21 |
Arrowhead Research Corporation |
Organic compositions to treat apoc3-related diseases
|
ES2949172T3
(es)
|
2014-07-16 |
2023-09-26 |
Novartis Ag |
Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
|
CN106604993A
(zh)
|
2014-07-29 |
2017-04-26 |
孟山都技术公司 |
用于控制昆虫害虫的组合物和方法
|
US11466061B2
(en)
|
2014-08-22 |
2022-10-11 |
Yingfang Liu |
Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins
|
CN107073294A
(zh)
|
2014-09-05 |
2017-08-18 |
阿克赛医药公司 |
使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
|
WO2016037053A1
(en)
|
2014-09-05 |
2016-03-10 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US11390885B2
(en)
|
2014-09-15 |
2022-07-19 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation
|
CA2962406A1
(en)
|
2014-09-25 |
2016-03-31 |
Cold Spring Harbor Laboratory |
Treatment of rett syndrome
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
WO2016077624A1
(en)
|
2014-11-12 |
2016-05-19 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
WO2016105517A1
(en)
|
2014-12-23 |
2016-06-30 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
BR112017015705A2
(pt)
|
2015-01-22 |
2018-03-20 |
Monsanto Technology Llc |
composições e métodos para controle de leptinotarsa
|
US20180036404A1
(en)
|
2015-03-02 |
2018-02-08 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
|
WO2016145003A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticle for treatment of gastric cancer
|
US10584144B2
(en)
|
2015-03-09 |
2020-03-10 |
University Of Kentucky Research Foundation |
RNA nanoparticles for brain tumor treatment
|
WO2016145008A2
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Mirna for treatment of breast cancer
|
KR101797569B1
(ko)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
|
WO2016161299A1
(en)
|
2015-04-01 |
2016-10-06 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
US10828381B2
(en)
|
2015-04-17 |
2020-11-10 |
University Of Kentucky Research Foundation |
RNA nanoparticles and method of use thereof
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
US10669528B2
(en)
|
2015-06-25 |
2020-06-02 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1(sod1)的核酸分子
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017013270A1
(en)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
CN115960235A
(zh)
|
2015-08-28 |
2023-04-14 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
WO2017044807A2
(en)
|
2015-09-09 |
2017-03-16 |
The Trustees Of Columbia University In The City Of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
WO2017059118A1
(en)
|
2015-09-29 |
2017-04-06 |
Duke University |
Compositions and methods for identifying and treating dystonia disorders
|
CN109563509B
(zh)
|
2015-10-19 |
2022-08-09 |
菲奥医药公司 |
靶向长非编码rna的减小尺寸的自递送核酸化合物
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
KR102162324B1
(ko)
|
2015-10-30 |
2020-10-07 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
ES2865030T3
(es)
|
2015-12-13 |
2021-10-14 |
Nitto Denko Corp |
Estructuras de ARNip para una alta actividad y una inespecificidad reducida
|
US11072777B2
(en)
|
2016-03-04 |
2021-07-27 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
|
WO2017161001A1
(en)
|
2016-03-15 |
2017-09-21 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
CN109476707B
(zh)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
WO2018057575A1
(en)
|
2016-09-21 |
2018-03-29 |
Alnylam Pharmaceuticals, Inc |
Myostatin irna compositions and methods of use thereof
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
BR112019012253A2
(pt)
|
2016-12-16 |
2020-01-28 |
Centre Hospitalier Univ Bordeaux |
inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
CN111050789A
(zh)
|
2017-06-15 |
2020-04-21 |
癌症进展有限公司 |
用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
|
US20200199541A1
(en)
|
2017-06-16 |
2020-06-25 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Blood vessel organoid, methods of producing and using said organoids
|
EP3589658A1
(en)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
WO2019047914A1
(zh)
|
2017-09-07 |
2019-03-14 |
北京泰德制药股份有限公司 |
靶向ckip-1的双链rna分子及其用途
|
KR20200044013A
(ko)
|
2017-09-11 |
2020-04-28 |
애로우헤드 파마슈티컬스 인코포레이티드 |
아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
|
UA127455C2
(uk)
|
2017-09-20 |
2023-08-30 |
4Д Молекьюлар Терапьютикс Інк. |
Капсид аденоасоційованого вірусу і спосіб його застосування
|
EP4219695A3
(en)
|
2017-11-27 |
2024-01-17 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
CA3083526A1
(en)
|
2017-12-06 |
2019-06-13 |
Andrew John Geall |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
AU2018392782B2
(en)
|
2017-12-21 |
2023-08-31 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
WO2019199673A1
(en)
|
2018-04-09 |
2019-10-17 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
CA3106535A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2020061381A1
(en)
|
2018-09-19 |
2020-03-26 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
PT3880212T
(pt)
|
2018-11-16 |
2024-02-08 |
Nitto Denko Corp |
Formulação e métodos de administração de rna de interferência para tumores malignos
|
WO2021037972A1
(en)
|
2019-08-27 |
2021-03-04 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
KR102100163B1
(ko)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
|
JP2023506842A
(ja)
|
2019-12-18 |
2023-02-20 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物及び方法
|
AU2020410514A1
(en)
|
2019-12-18 |
2022-06-30 |
Novartis Ag |
3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN115243763A
(zh)
|
2020-01-08 |
2022-10-25 |
里珍纳龙药品有限公司 |
治疗进行性骨化性纤维发育不良
|
WO2021150300A1
(en)
|
2020-01-22 |
2021-07-29 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
US11642407B2
(en)
|
2020-02-28 |
2023-05-09 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
JP2023537798A
(ja)
|
2020-03-19 |
2023-09-06 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
CA3219898A1
(en)
|
2021-05-28 |
2023-11-21 |
Wentao Zhang |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
WO2022269518A2
(en)
|
2021-06-23 |
2022-12-29 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
WO2024059618A2
(en)
|
2022-09-13 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed tgfbr shrnas
|
WO2024059824A2
(en)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|